Novartis raises 2026 core operating income outlook to flat to low-single-digit growth
Bitget2026/10/27 06:01- Novartis raised its 2026 core operating income outlook to flat to low-single-digit growth at constant currencies, from a low-single-digit decline.
- Net sales remain forecast to grow by a low-single-digit percentage at constant currencies.
- Third-quarter core operating income rose 10% at constant currencies to USD 6.04 billion; core margin reached 41.6%.
- Quarterly sales increased 4% at constant currencies to USD 14.52 billion, driven by priority brands and launches.
- The group reaffirmed 5%-6% sales CAGR for 2025-2030, with mid-single-digit long-term growth, both at constant currencies.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.
AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).
Tom Lee Says Democratic Sweep Could Fuel 15% to 20% Tech Rally
Crypto prices
More
